Good day, dear subscriber,
This is the first in a series of preventive cardiology profiles I'll be publishing over the next year. These patient stories aim to help readers better understand their heart-related medication, imaging, surgical, dietary, lifestyle, and device options.
Articles from The Skeptical Cardiologist have always been free and free of adverts, both on WordPress since 2013 and Substack since 2022. However, starting next week, I will be activating payments on this Substack.
This means that if you have pledged support, you will be charged and converted to a paid subscription. Paid subscribers will gain access to comments and select posts, along with bonus AMA sessions. Part 2 of this article, which delves into the AI tool HeartFlow for analyzing coronary CT angiograms, will be exclusive to paid subscribers.
In June of 2024 I saw in my Encinitas cardiology office a seventy-year-old man (we’ll call Bernard) who grew up a block from the beach, started surfing at age 12 years, and was still surfing five times a week at a very high level.
He had no symptoms but had balked at taking a statin drug recommended by his primary care physician earlier in the year. This is a common response among those who have been incredibly healthy, health-conscious with respect to diet and lifestyle, and physically active their entire lives.
Such individuals do not feel it is possible that they could have developed advanced plaque in their coronary arteries or be at high risk for cardiovascular disease like heart attack or stroke. Coupled with the belief that their lifestyle and physical activity protect them, we often encounter a distrust of prescription medications and a fear that taking such medications puts them in the category of the infirm.
In addition, there was no history of premature heart disease in his family. His dad had lived to 99 years of age and was sharp up until his death, mom died from diabetes at age 68.
His PCP had recommended a statin to him after his last cholesterol testing, which came back with an LDL-C of 145. If we plug Bernard’s age, gender, BP and cholesterol numbers into the ACC/AHA ASCVD risk estimator,1it gives him a 16.5% risk of heart attack/stroke in the next 10 years, which is considered “intermediate” and for which statin therapy is recommended.
This is not surprising since (as I discuss here) almost every man over the age of 60 years according to that ASCVD risk estimator will have an ASCVD risk >7.5% which triggers a guideline recommendation of statin therapy.
But Bernard was not your average seventy year old man, he looked and felt like someone 10 to 20 years younger and we needed more definitive information on his personal risk to be certain that he needed to begin lipid-lowering medications. That definitive information is easily available in this age group with a coronary artery calcium (CAC) scan.
The Power of the Coronary Calcium Scan in Identifying Early Plaque and Refining Individual ASCVD Risk
A coronary artery calcium scan had been obtained by his PCP and as we have written about extensively this is the simplest, most accurate way to personalize the individual’s risk of heart attack and stroke. I’ve seen patients like Bernard who have had zero scores (17% of 70 year old men have a zero CAC) and don’t need therapy.
Conversely, I’ve gotten very high scores reflecting severe coronary plaque buildup and a much higher risk than the population estimates.
Bernard thought his CAC score was 125 at our first visit. Using the MESA data risk estimator2we know 125 is actually below the average CAC score for a 70-year-old white males. (For the same-aged woman, it is at the 75th percentile and would be quite worrisome.)
When I tracked down the actual report, however, his total score was 1267 which is at the 98th percentile for men his age. (I’m pretty sure Bernard confused ICD-10-CM code for coronary atherosclerosis due to calcified coronary lesions on the report, I25.84 , with the actual CAC score.)
The MESA online risk estimator calculates the 10-year risk of coronary heart disease events alone and compares that risk with and without the CAC score. Without the CAC score, it estimated Bernard’s 10-year heart attack risk as 5.9% but using the CAC score it was doubled at 13.5%
Very rarely, I have come across falsely high CAC3 scores so I obtained a CD of his scan from Palomar and reviewed it myself. This showed extensive calcium distributed evenly through all three arteries.
Next Steps after Diagnosing Advanced Atherosclerosis in the Active Asymptomatic
Bernard had overcome his reluctance to take a statin when his CAC results were shared with him. His PCP started him on 20 mg of atorvastatin and a baby aspirin.
The value of the CAC score and the ability to share with the patient direct visualization of the calcified plaques in the heart cannot be overstated. Many patients who were hesitant or on the fence about treatment become highly motivated to take statins (or other effective medications if they have a strong bias against or fear of statins) after realizing they have silently built up extensive coronary plaque.
Sharing the images of the calcifications in the coronary has been shown to be even more motivating.
Bernard was referred by his PCP to a cardiologist who had wanted him to get a “dye stress test.”
At the first visit, I spent a long time explaining to him why I did not recommend stress testing for very active individuals with high CAC scores and no symptoms. In particular, I’m not a fan of nuclear stress testing, which has a very high rate of false positive results (low specificity).
We went over the results of the ISCHEMIA trial which did not show any benefits of a more aggressive, invasive approach over optimal medical therapy in stable patients with significantly blocked coronary arteries.
Bernard had a nice drop in his LDL down to 79 with the atorvastatin. His apo B was 60 and his hs-CRP (measure of inflammation) was <0.20.
We had halved his risk for heart attack and stroke over the next ten years. This was a great start considering his concerns about medication but I felt we could do better.
Symptoms Develop, Are They Cardiac? Are They Side Effects?
At his second visit, 2 weeks later, Bernard shared with me his unhappiness about being on a prescription medication for the first time in his life. In addition, he had developed left shoulder pain.
I felt the pain was most likely musculoskeletal and not statin-associated muscle ache (myalgia) and given his advanced subclinical atherosclerosis and high risk for a cardiac event I prefered not to stop statin treatment. So we agreed to switch to 10 mg rosuvastatin which in my experience has less myalgias with equal efficacy to 20 mg atorvastatin.
Bernard again brought up the stress test that had been ordered by his previous cardiologist. Given his need for further reassurance and considering that he was having a pain in the chest region that could conceivably be angina and given that he was out in the Pacific ocean 5 days per week engaging in extremely vigorous physicial activity I ordered a stress echocardiogram.
I also discussed coronary CT angiography as an option at this visit but he preferred the stress test.
He did great on the stress echo with outstanding exercise tolerance for his age, completing 12 minutes of a Bruce Protocol (Stage IV) and achieving a heart rate of 144 beats per minute with absolutely no chest pain, ECG changes or abnormalities on the echo to suggest limited blood flow.
His left shoulder pain turned out to be due to bursitis and slowly improved after steroid injection and physical therapy. He was able to get back to surfing regularly.
An Iatrogenic Catastrophe Delays Achieving Optimal Lipid Levels
I did not see Bernard again for 6 months. When I saw him back in April of this year I was surprised to hear that he had had a severe complication of a screening colonoscopy (performed by a physician not in our medical system in an outpatient setting.)
He had suffered a colon perforation during a routine screening colonoscopy, resulting in severe abdominal pain, life-threatening hypotension, shock and a 2-day hospitalization.
It took him weeks to recover from this event and during that time he understandably wanted to focus on enjoying life. Consequently, he put off repeat lipid testing and follow-up.
Unfortunately, his LDL had bumped up since our last testing and now was 83. 4
In primary prevention of coronary disease the goal LDL-C per guidelines is <100 but if we have identified very advanced coronary plaque as in this case, they have risk which is as great as or greater than someone who has already had a heart attack and I want to see LDL-C levels at least <70 .
If the patient has very advanced subclinical atherosclerosis and wants to cause regression of the soft plaque that is present, stop new plaque formation and eliminate the possibility of coronary events, then I recommend an even lower goal of <55 for LDL-C.
Achieving Optimal Risk Reduction and Coronary Plaque Characterization
Despite his initial reluctance, Bernard was now fully motivated and open to more aggressive lipid-lowering therapy. Options at this point were increasing the dosage of rosuvastatin or adding a second drug.
We also had a long discussion on whether his diet and lifestyle were optimized. He was following an exemplary diet, exercised regularly, didn’t smoke, was not overweight and had minimal stress.
I didn’t feel we would achieve optimal LDL-C/apo B goals in him by tweaking diet or lifestyle.
I’ll discuss in detail the medical option we chose in Part III of this article.
HeartFlow Analysis
Bernard had noticed some shortness of breath when he was really pushing himself during activities and he was now open to undergoing a CT coronary angiogram to fully characterize the plaque in his coronary arteries.
After a full discussion of the risks and benefits of a CCTA we agreed to proceed.
In the last year CMS has begun covering an AI add-on to CCTA called HeartFlow.
I’ve discussed in detail in prior posts the AI CCTA add-on CLEERLY and in Part 2 of the Senior Surfer we’ll look at what HeartFlow adds to our assessment of coronary plaque and prevention of coronary events.
Maunderingly Yours,
-ACP
**10-year risk for ASCVD is categorized as:
Low-risk (<5%)
Borderline risk (5% to 7.4%)
Intermediate risk (7.5% to 19.9%)
High risk (≥20%)
The MESA (Multi-ethnic Study of Atherosclerosis) study is an ongoing follow-up of 6000 individuals and it risk estimator provides an accurate estimate of 10-year CHD risk (MI, cardiac arrest, confirmed angina requiring revascularization, CHD death) The Coronary Age calculator provides a convenient transformation of the MESA 10-year CHD Risk Score into a scale that may be more easily appreciated by both patients and treating physicians.
When LDL/Apo B increases in a patient on lipid-lowering therapy we consider several possibilities
patient not taking medication consistently
diet, lifestyle, weight management has regressed
if none of the above (as in Bernard’s case) this is most likely due to increase intestinal absorption of cholesterol in response to the reduced synthesis of LDL caused by atorvastatin (https://www.atherosclerosis-journal.com/article/S0021-9150(23)00232-0/fulltext)


“Nicely written, Anthony. Bernard’s case shows how lifestyle and biology can tell very different stories. A high calcium score shatters the illusion of invincibility — but it also raises a harder question: are all high scores the same? We know many patients with heavy calcification have stable disease. And then there are long-distance runners, often carrying high calcium scores but low event rates. Maybe calcium is a marker, but the mechanisms — and the risks — aren’t one-size-fits-all. What do you think?”
Great article and I’ve personally had many similar conversations and clinical stories. I really enjoy how you shared how you approach patient care and education to help guide the patient on their specific journey. Patient - physician relationship and decision-making are so important.